Respiratory syncytial virus (RSV) vaccine
Learn more about participating in the ConquerRSV trial for a potential vaccine to prevent respiratory syncytial virus (RSV) infection. RSV is a common respiratory virus that infects the lungs and airways. It is the second leading cause of significant respiratory disease in adults, behind the flu.
There is currently no approved treatment or vaccine for RSV. The ConquerRSV trial is studying an experimental vaccine aimed at helping your body's immune system protect itself against RSV.
This clinical trial seeks to recruit adult volunteers. To register, you must:
- Be 60 or older
- To be in a good health
- Certain chronic conditions such as heart failure and chronic obstructive pulmonary disease are not necessarily a barrier to participation.
- Be independent (you do not need assistance to take care of yourself)
By participating in this clinical trial, you may be able to change the future of the fight against RSV.
I want to apply to this clinical study
The study process in pictures
Step 1 | Before starting the study, we will take time to fully explain the selection process and the conduct of the study by phone.
Step 2 | After the initial phone interview, if you are still interested in taking part in a study, we schedule a preliminary meeting with you during which you may ask all the questions you wish and take the time you require to read over the consent form. This form explains, in detail, the different stages of each study.
Step 3 | You may make a decision at that time to move forward with or terminate the selection process. However, you are under no obligation to make an immediate decision. Based on briefing content, you may take the time necessary to come to a decision and consult with your personal physician or loved ones.
Step 4 | Depending on the nature of the study, some tests or medical examinations may be required. In the majority of cases, these tests or examinations are conducted on Diex Research premises based on your individual availability.
Step 5 | If you are eligible, you may then begin a clinical study with us.